Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma

Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma

The therapeutic efficacy of dendritic cell (DC)-based immunotherapy may be potentiated in combination with other anticancer therapies that enhance DC function by modulating immune responses and the tumor microenvironment. In this study, we investigated the efficacy of DC vaccination in combination w...

Full description

Bibliographic Details
Main Authors: Manh-Cuong Vo, Sung-Hoon Jung, Tan-Huy Chu, Hyun-Ju Lee, Thangaraj Jaya Lakshmi, Hye-Seong Park, Hyeoung-Joon Kim, Joon Haeng Rhee, Je-Jung Lee
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-06-01
Series:Frontiers in Immunology
Subjects:
myeloma
dendritic cells
lenaldiomide
anti-PD-1
cancer immunotherapy
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.01370/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.01370/full

Similar Items